## **Raymond Y Huang**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1274491/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Artificial intelligence in cancer imaging: Clinical challenges and applications. Ca-A Cancer Journal for Clinicians, 2019, 69, 127-157.	329.8	965
2	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
3	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
4	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
5	C. elegans ORFeome version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression. Nature Genetics, 2003, 34, 35-41.	21.4	347
6	Artificial Intelligence Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT. Radiology, 2020, 296, E156-E165.	7.3	315
7	Residual Convolutional Neural Network for the Determination of <i>IDH</i> Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081.	7.0	297
8	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology, 2017, 19, 109-117.	1.2	211
9	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
10	Defining language networks from restingâ€state fMRI for surgical planning—a feasibility study. Human Brain Mapping, 2014, 35, 1018-1030.	3.6	176
11	Structural genomics: A pipeline for providing structures for the biologist. Protein Science, 2002, 11, 723-738.	7.6	168
12	Ivosidenib in Isocitrate Dehydrogenase 1 <i>–</i> Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
13	Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy ââ,¬â€œ Detecting Illusive Disease, Defining Response. Frontiers in Neurology, 2015, 6, 33.	2.4	139
14	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
15	Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro-Oncology, 2019, 21, 1412-1422.	1.2	128
16	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2019, 21, 26-36.	1.2	114
17	Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS ONE, 2017, 12, e0187908.	2.5	109
18	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102

#	Article	IF	CITATIONS
19	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
20	Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Journal of Neuro-Oncology, 2019, 142, 299-307.	2.9	98
21	Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro-Oncology, 2016, 18, 1680-1687.	1.2	94
22	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology, 2018, 20, 1162-1172.	1.2	92
23	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	1.2	92
24	Center for Synchrotron Biosciences' U2B beamline: an international resource for biological infrared spectroscopy. Journal of Synchrotron Radiation, 2002, 9, 189-197.	2.4	86
25	Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging. Clinical Cancer Research, 2020, 26, 1944-1952.	7.0	86
26	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2017, 19, 1688-1697.	1.2	84
27	Metalloproteomics: High-Throughput Structural and Functional Annotation of Proteins in Structural Genomics. Structure, 2005, 13, 1473-1486.	3.3	76
28	In situ chemistry of osteoporosis revealed by synchrotron infrared microspectroscopy. Bone, 2003, 33, 514-521.	2.9	72
29	Characterization of bone mineral composition in the proximal tibia of Cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. Bone, 2002, 30, 492-497.	2.9	66
30	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
31	PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology, 2018, 91, e1355-e1359.	1.1	64
32	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical Cancer Research, 2016, 22, 575-581.	7.0	62
33	Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study. American Journal of Neuroradiology, 2018, 39, 2187-2193.	2.4	61
34	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncology, 2019, 21, i32-i43.	1.2	56
35	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 2017, 23, 5745-5756.	7.0	53
36	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	1.2	45

#	Article	IF	CITATIONS
37	Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data. European Radiology, 2022, 32, 205-212.	4.5	42
38	Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. Journal of Neuro-Oncology, 2014, 119, 149-158.	2.9	41
39	Imaging in neuro-oncology. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875986.	3.5	41
40	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	1.2	39
41	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro-Oncology, 2022, 24, 101-113.	1.2	38
42	Automatic Machine Learning to Differentiate Pediatric Posterior Fossa Tumors on Routine MR Imaging. American Journal of Neuroradiology, 2020, 41, 1279-1285.	2.4	37
43	Evaluation of a convolutional neural network for ovarian tumor differentiation based on magnetic resonance imaging. European Radiology, 2021, 31, 4960-4971.	4.5	35
44	Semi-Automatic Segmentation Software for Quantitative Clinical Brain Glioblastoma Evaluation. Academic Radiology, 2012, 19, 977-985.	2.5	33
45	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro-Oncology, 2018, 20, 1262-1271.	1.2	31
46	Deep Learning Based on <scp>MRI</scp> for Differentiation of Low―and Highâ€Grade in Lowâ€5tage Renal Cell Carcinoma. Journal of Magnetic Resonance Imaging, 2020, 52, 1542-1549.	3.4	31
47	Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMTÂmethylation, EGFR status and pretreatment MRI in determining response and survival. Journal of Neuro-Oncology, 2013, 115, 267-276.	2.9	30
48	Functional MRI Task Comparison for Language Mapping in Neurosurgical Patients. Journal of Neuroimaging, 2019, 29, 348-356.	2.0	28
49	Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro-Oncology, 2022, 24, 289-299.	1.2	28
50	Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer, 2013, 119, 3479-3488.	4.1	26
51	The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis. European Radiology, 2021, 31, 5289-5299.	4.5	26
52	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 705-718.	1.1	25
53	High-throughput expression, purification, and characterization of recombinant Caenorhabditis elegans proteins. Biochemical and Biophysical Research Communications, 2003, 307, 928-934.	2.1	23
54	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology, 2020, 22, 1822-1830.	1.2	23

#	Article	IF	CITATIONS
55	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro-Oncology, 2014, 16, 1523-1529.	1.2	22
56	Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. European Radiology, 2021, 31, 4114-4129.	4.5	22
57	An automated COVID-19 triage pipeline using artificial intelligence based on chest radiographs and clinical data. Npj Digital Medicine, 2022, 5, 5.	10.9	22
58	The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study). American Journal of Neuroradiology, 2015, 36, 1589-1598.	2.4	21
59	Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base. World Neurosurgery, 2018, 112, e812-e822.	1.3	21
60	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurologic Clinics, 2020, 38, 95-113.	1.8	21
61	Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non–Small Cell Lung Cancer. Radiology, 2020, 297, 419-427.	7.3	21
62	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	7.0	20
63	Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients. World Neurosurgery, 2018, 118, e375-e387.	1.3	18
64	Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas. Journal of Neuro-Oncology, 2018, 139, 563-571.	2.9	17
65	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro-Oncology, 2019, 21, 234-241.	1.2	16
66	The Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1785.	3.7	16
67	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncology, 2018, 85, 29-34.	1.5	15
68	Effect of disease and recovery on functional anatomy in brain tumor patients: insights from functional MRI and diffusion tensor imaging. Imaging in Medicine, 2013, 5, 333-346.	0.0	14
69	Diagnosis and treatment of a perforated duodenal diverticulum. Emergency Radiology, 2007, 13, 285-287.	1.8	13
70	How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas. Current Treatment Options in Neurology, 2015, 17, 343.	1.8	13
71	Assessment of care pattern and outcome in hemangioblastoma. Scientific Reports, 2018, 8, 11144.	3.3	13
72	Development of Brain Metastases in Patients With Non–Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. American Journal of Roentgenology, 2021, 217, 1184-1193.	2.2	13

#	Article	IF	CITATIONS
73	CT and MRI Protocol Variation andÂOptimization at an Academic MedicalÂCenter. Journal of the American College of Radiology, 2018, 15, 1254-1258.	1.8	12
74	MR Imaging of the Extracranial Facial Nerve with the CISS Sequence. American Journal of Neuroradiology, 2019, 40, 1954-1959.	2.4	12
75	Differentiation of low and high grade renal cell carcinoma on routine MRI with an externally validated automatic machine learning algorithm. Scientific Reports, 2020, 10, 19503.	3.3	12
76	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584.	3.4	12
77	Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. American Journal of Neuroradiology, 2022, 43, 675-681.	2.4	12
78	An Update on the Approach to the Imaging of Brain Tumors. Current Neurology and Neuroscience Reports, 2017, 17, 53.	4.2	11
79	The effect of brain metastasis location on clinical outcomes: A review of the literature. Neuro-Oncology Advances, 2019, 1, vdz017.	0.7	11
80	Intra- and Intersubspecialty Variability in Lumbar Spine MRI Interpretation: A Multireader Study Comparing Musculoskeletal Radiologists and Neuroradiologists. Current Problems in Diagnostic Radiology, 2020, 49, 182-187.	1.4	11
81	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagnostic Pathology, 2016, 11, 13.	2.0	10
82	Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. American Journal of Roentgenology, 2018, 211, 1342-1347.	2.2	10
83	Survival Benefit of Adjuvant Radiotherapy in Elderly Patients with WHO Grade III Meningioma. World Neurosurgery, 2019, 131, e303-e311.	1.3	10
84	Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data. Neuro-Oncology, 2020, 22, 1536-1544.	1.2	10
85	Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2021, 216, 1172-1182.	2.2	9
86	Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. Cancer Imaging, 2022, 22, 19.	2.8	9
87	A low percentage of metastases in deep brain and temporal lobe structures. Neuro-Oncology, 2019, 21, 640-647.	1.2	8
88	CerebroVis: Designing an Abstract yet Spatially Contextualized Cerebral Artery Network Visualization. IEEE Transactions on Visualization and Computer Graphics, 2020, 26, 938-948.	4.4	8
89	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 3369.	3.7	8
90	Standardization of imaging methods for machine learning in neuro-oncology. Neuro-Oncology Advances, 2020, 2, iv49-iv55.	0.7	8

6

#	Article	IF	CITATIONS
91	Early Postoperative Imaging and Image-Guided Procedures on Patients with Face Transplants. American Journal of Neuroradiology, 2015, 36, 568-574.	2.4	6
92	Response assessment in high-grade glioma: tumor volume as endpoint. Neuro-Oncology, 2017, 19, 744-745.	1.2	6
93	Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. World Neurosurgery, 2019, 122, e108-e120.	1.3	5
94	Frequency and Evolution of New Postoperative Enhancement on 3 Tesla Intraoperative and Early Postoperative Magnetic Resonance Imaging. Neurosurgery, 2020, 87, 238-246.	1.1	5
95	Whole-Brain MR Spectroscopy Imaging of Brain Tumor Metabolites. Radiology, 2020, 294, 598-599.	7.3	5
96	Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell lymphoma of head and neck with extranodal involvement. Hematology, 2019, 24, 268-275.	1.5	4
97	Target-specific yield rate and clinical utility of percutaneous tissue sampling in spinal infection. Clinical Imaging, 2020, 68, 257-262.	1.5	4
98	Standardized Classification of Lumbar Spine Degeneration on Magnetic Resonance Imaging Reduces Intra- and Inter-subspecialty Variability. Current Problems in Diagnostic Radiology, 2022, 51, 491-496.	1.4	4
99	Imaging Advances for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 43-61.	2.2	4
100	Effect of region-of-interest placement in bolus tracking cerebral computed tomography angiography. Neuroradiology, 2013, 55, 1183-1188.	2.2	3
101	CT-Guided Percutaneous Spine Biopsy Specimen Adequacy, Pathology Concordance, and Negative Predictive Value with Battery-Powered Drill and Manual Approaches. Current Problems in Diagnostic Radiology, 2019, 48, 558-562.	1.4	3
102	Non-invasive diagnosis of H3 K27M mutant midline glioma. Neuro-Oncology, 2020, 22, 309-310.	1.2	3
103	Encephalopathy at admission predicts adverse outcomes in patients with SARSâ $\in$ CoVâ $\in$ 2 infection. CNS Neuroscience and Therapeutics, 2021, 27, 1127-1135.	3.9	3
104	Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. Neuro-Oncology, 2022, 24, 482-491.	1.2	3
105	Identification and Characterization of Leptomeningeal Metastases Using SPINE, A Webâ€Based Collaborative Platform. Journal of Neuroimaging, 2021, 31, 324-333.	2.0	3
106	Biopsy Artifact in Laser Interstitial Thermal Therapy: A Technical Note. Frontiers in Oncology, 2021, 11, 746416.	2.8	3
107	Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. Neuro-Oncology Advances, 2021, 3, vdab088.	0.7	2
108	Recurrent glioblastoma: Stratification of patient survival using tumor volume before and after antiangiogenic treatment. Journal of Clinical Oncology, 2013, 31, 2075-2075.	1.6	2

#	Article	IF	CITATIONS
109	Deep learning approaches to non-invasively assess molecular features of gliomas. Neuro-Oncology, 2022, 24, 653-654.	1.2	2
110	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
111	Radiographic Prediction of Meningioma Grade and Genomic Profile. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	1
112	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii11-ii11.	1.2	1
113	Indications and Limitations of Conventional Imaging– Current Clinical Practice in theÂContext of Standard Therapy. , 2020, , 1-15.		1
114	MNGI-10. SURVIVAL BENEFIT ASSOCIATED WITH ADJUVANT RADIOTHERAPY IN ELDERLY PATIENTS WITH WHO GRADE III MENINGIOMA. Neuro-Oncology, 2017, 19, vi134-vi134.	1.2	0
115	Imaging Neurologic Manifestations of Oncologic Disease. , 2018, , 13-31.		0
116	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. Neuro-Oncology, 2018, 20, vi159-vi159.	1.2	0
117	NIMG-54. SPATIAL DISTRIBUTION ATLASES OF POST-TREATMENT MRI SCANS REVEAL DISTINCT HEMISPHERIC DISTRIBUTION OF GLIOBLASTOMA RECURRENCE FROM PSEUDO-PROGRESSION. Neuro-Oncology, 2018, 20, vi188-vi188.	1.2	0
118	Using 3D MRI Anatomic Maps to Determine Prognosis for Glioblastomas. Radiology, 2019, 293, 644-645.	7.3	0
119	DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS. Neuro-Oncology, 2019, 21, vi73-vi73.	1.2	0
120	NIMG-43. LONGITUDINAL TRACKING AND GROWTH RATE CHARACTERIZATION OF BRAIN METASTASES ON MAGNETIC RESONANCE IMAGING. Neuro-Oncology, 2019, 21, vi170-vi171.	1.2	0
121	Teaching NeuroImages: Corkscrew medullary veins in active neurosarcoidosis. Neurology, 2019, 93, e1832-e1833.	1.1	0
122	In search of predictive and response markers in antiangiogenic therapy of glioblastoma. Neuro-Oncology, 2021, 23, 184-185.	1.2	0
123	BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas. Neuro-Oncology, 2021, , .	1.2	0
124	Improved Optic Nerve Visualization and Surgical Planning through a Novel MRI Protocol. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.8	0
125	Performance of Automatic Machine Learning versus Radiologists in the Evaluation of Endometrium on Computed Tomography. SSRN Electronic Journal, 0, , .	0.4	0
126	Differentiation of Low and High Grade Renal Cell Carcinoma on Routine MR with an Externally Validated Automatic Machine Learning Algorithm. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	CITATIONS
127	NIMG-24. RANO CRITERIA DETECTS EARLY PROGRESSION SOONER THAN MODIFIED RANO CRITERIA IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi133-vi133.	1.2	0
128	BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii8-ii9.	1.2	0
129	Is this good enough? On expert perception of brain tumor segmentation quality. , 2022, , .		0